Revenue Breakdown
Composition ()
No data
Revenue Streams
OmniAb Inc (OABI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is License and milestone revenue, accounting for 83.4% of total sales, equivalent to $12.03M. Other significant revenue streams include Service revenue and Royalty revenue. Understanding this composition is critical for investors evaluating how OABI navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, OmniAb Inc maintains a gross margin of 58.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -54.27%, while the net margin is -53.42%. These profitability ratios, combined with a Return on Equity (ROE) of -20.25%, provide a clear picture of how effectively OABI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, OABI competes directly with industry leaders such as SLN and GOTU. With a market capitalization of $339.24M, it holds a significant position in the sector. When comparing efficiency, OABI's gross margin of 58.11% stands against SLN's 97.39% and GOTU's 69.53%. Such benchmarking helps identify whether OmniAb Inc is trading at a premium or discount relative to its financial performance.
